ERBB2 and Hodgkins lymphoma: Both revolutionized treatment for their respective indication (relapsed Hodgkin's lymphoma (HL)/systemic anaplastic large cell lymphoma (sALC), and Her2-positive breast cancer), while denileukin difitox (OntakTM) and, gemtuzumab ozogamicin (GO; MylotargTM) have seen limited clinical use.